Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Infliximab + vitamin D is a combination therapy that has shown synergistic effects in treating inflammatory bowel diseases, particularly Crohn's disease. Infliximab is a TNF-α inhibitor that reduces inflammation, while vitamin D acts as an immunomodulator. Studies have shown that patients with low vitamin D levels who initiate infliximab treatment are more likely to achieve clinical remission. The combination therapy works by regulating regulatory T cell (Treg) differentiation and modulating inflammatory cytokines such as IL-6, IL-8, IL-10, and TNF-α. High-dose vitamin D treatment combined with infliximab has been shown to reduce the need for infliximab dose escalation and decrease inflammatory markers in Crohn's disease patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on infliximab + vitamin D.